Weekly Top News – Psoriasis – May 20, 2019

May 20, 2019

Tremfya (guselkumab) / J&J
Tremfya: Regulatory submissions in US/EU for Crohn’s disease and ulcerative colitis between 2019-2023 (J&J) – May 16, 2019 – Pharmaceutical Business Review: Regulatory submissions in US/EU for personalized dosing psoriasis between 2019-2023


benvitimod (GSK2894512) / Roivant
A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults (clinicaltrials.gov) – May 20, 2019 – P3; N=500; Not yet recruiting; Sponsor: Dermavant Sciences GmbH


Siliq (brodalumab) / Bausch Health, Leo Pharma, Kyowa Hakko Kirin
Psoriasis, brodalumab is redeemable in Italy (AboutPharma) – May 17, 2019 – “The first biological drug from LEO Pharma arrives in Italy: a monoclonal antibody against moderate-severe plaque psoriasis. In fact, brodalumab was repaid in Italy…The OK of the Italian Drug Agency, approved in recent weeks, was announced yesterday in Rome by LEO Pharma.”


Cosentyx (secukinumab) / Novartis; bimekizumab (UCB4940) / UCB
BE RADIANT: A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) – May 13, 2019 – P3; N=743; Active, not recruiting; Sponsor: UCB Biopharma S.P.R.L.; Recruiting –> Active, not recruiting


Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) – May 14, 2019 – P3; N=100; Recruiting; Sponsor: AbbVie; Not yet recruiting –> Recruiting


Otezla (apremilast) / Celgene
Otezla pricing: Wholesale acquisition cost of $3398/month (Jefferies) – May 15, 2019 – A subscription to Thomson ONE is required to gain full access to report 67209046; Page no: 67; REPORT TITLE: “Initiating microbiome-based therapeutics: Novel science poised for NT success”; AUTHOR: Song, Roger, et al; DATE: 04/30/2019


ABBV-157 / AbbVie, Inventiva
Q1 2019 financial information and corporate business update (GlobeNewswire) – May 15, 2019 – “AbbVie continues the clinical development of ABBV-157, the drug candidate resulting from its collaboration with Inventiva. Following a first Phase I clinical trial, AbbVie recently reported its intention to initiate a new clinical study with ABBV-157, aiming at assessing the compound’s pharmacokinetics, safety and tolerance in healthy volunteers and in patients with chronic plaque psoriasis.”


Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Ilumya sales projection: $120M (consensus: $200-300M) peak (Credit Suisse) – May 14, 2019 – A subscription to Thomson ONE is required to gain full access to report 67226255; Page no: 4; REPORT TITLE: “Credit Suisse India Daily: Top stories and ideas”; AUTHOR: Gupta, Ashish, et al; DATE: 05/02/2019


Stelara (ustekinumab) / J&J
“Ustekinumab Offers Better Drug Survival to Treat Pediatric Psoriasis https://t.co/0qjn7PNced @NPF” (@NPFjim) – May 17, 2019


MP1032 / MetrioPharm
EQS-News: MetrioPharm AG: MetrioPharm AG publishes annual report for 2018 (Business Insider) – May 16, 2019 – “In the past fiscal year, we were able to decisively advance the development of our lead compound MP1032. Phase II clinical trial successfully initiated…for the indication psoriasis started. Patient recruitment has now been completed to our satisfaction.”


Cosentyx (secukinumab) / Novartis
Cosentyx TRx trend: +38% till date in Q2 2019 (J.P. Morgan) – May 18, 2019 – A subscription to Thomson ONE is required to gain full access to report 67253598; Page no: 1; REPORT TITLE: “European Pharmaceuticals: Weekly chartbook: TRx for week ending 26th April”; AUTHOR: Vosser, Richard, et al; DATE: 05/06/2019

No Comments

Post a Comment